Axsome Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
March 07, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
Interim analyses of STRIDE-1 and ADVANCE-1 trials of AXS-05 anticipated in 2018 Company to host conference call today at 8:00 AM Eastern NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- Axsome...
Axsome Therapeutics Announces Primary Endpoint Met in Phase 1 Trial of Next Generation Product Candidate AXS-09 Containing Chirally Pure Esbupropion and Dextromethorphan
February 26, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
Chirally pure and stable single enantiomers of bupropion achieved AXS-09 consists of esbupropion and dextromethorphan for CNS disorders Esbupropion is the chirally pure S-enantiomer of bupropion ...